AVXL
Anavex Life Sciences Corporation
-22.55%
$11.75 - $9.10
Feb 7th 2023 - Mar 21st 2023
Jan, 23, 2023
“Statistically significant improvements in lung fu... See more
Dec, 3, 2022
Anavex said that the candidate's safety profil... See more
BCRX
Biocryst Pharmaceuticals Inc.
-23.50%
$10.68 - $8.17
Feb 7th 2023 - Mar 21st 2023
Jan, 9, 2023
"We believe BCX10013 has the potential to be ... See more
Dec, 10, 2022
Safety profile is decent.
Jan, 23, 2023
“Statistically significant improvements in lung function, symptoms and quality of life 36% reduction in rate of exacerbations over 24 weeks Well tolerated safety profile over 48 weeks NDA submission planned for 1H 2023” Oh, 48 weeks! !
Dec, 3, 2022
Anavex said that the candidate's safety profile also appeared to be relatively good.
Nov, 30, 2022
Anavex also better in ADAS-Cog14, and far superior safety profile.
Nov, 18, 2022
>> no clinically significant treatment-related adverse events and no serious adverse events = PERFECT SAFETY PROFILE !!
Nov, 14, 2022
$AVXL safety profile = excellent !!
Oct, 30, 2022
with Blarcamesine's outstanding safety profile this will become the #1 off label prescribed drug in the world.
Oct, 4, 2022
$AVXL for Hans, yes $avxl is great and will get approved when it’s high dose arm absolutely crushes the current SOC with a flawless safety profile.
Jan, 9, 2023
"We believe BCX10013 has the potential to be a best-in-class treatment option with an oral, once-daily profile,”
Dec, 10, 2022
Safety profile is decent.